Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
About this trial
This is an interventional treatment trial for Lymphatic Filariasis focused on measuring moxidectin, ivermectin
Eligibility Criteria
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Male or female, aged 18-70 years
- In good general health as evidenced by medical history
- Peripheral night blood W. bancrofti Mf levels ≥40 Mf/mL
- No history of taking antifilarial medications in past 12 months
- Resident of the study area with no plans to change residence in the next 36 months
- For women of childbearing potential, willing to use appropriate method of contraception for one month following each treatment
Exclusion Criteria:
- Pregnancy or currently breastfeeding
- Known allergic reactions to any of the study medications
- Evidence of severe or systemic comorbidities (aside from features of filarial disease), as judged by the principal investigator
- Baseline biochemical abnormalities, as indicated by AST, ALT, or creatinine > 2 times the upper limit of normal
- Evidence of urinary tract infection as indicated by 3+ nitrites on dipstick (individuals with 1+ or 2+ nitrites will not be excluded) or underlying chronic kidney disease as indicated by 3+ protein or 3+ blood on urine dipstick exam
- Hgb < 7 gm/dL (any such individuals will be referred to the local health center for evaluation and treatment)
- Positive skin snip for onchocerciasis
Sites / Locations
- Regional Hospital of Agboville, Southern Cote d'Ivoire
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
IA (Ivermectin + Albendazole)
MoxA (Moxidectin + Albendazole)
IDA (Ivermectin + Diethylcarbamazine + Albendazole)
MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)
Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.